Bismuth subnitrate 20% / Iodoform 40% paste impregnated gauze dressing 2.5cm x 100cm
Available from pharmacies, supermarkets, and retail outlets
Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic agent [A33012].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Bismuth subnitrate + Iodoform
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Bismuth subnitrate + Iodoform on the MHRA register
Bismuth subnitrate 20% / Iodoform 40% paste impregnated gauze dressing 2.5cm x 100cm
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 1 · 1933–2025
Showing the 50 most relevant studies, sorted by most relevant.
D. R. Halalmeh, Yusuf Ansari, Arwa Jader, et al.
Cureus, 2024
M. Mateblowski, P. Topfmeier, M. Fischer, et al.
1993
Ângela Gonçalves, Mariana Matias, Jorge A. R. Salvador, et al.
International Journal of Molecular Sciences, 2024
- Bismuth
- Organometallic Compounds
- Peptic Ulcer
Cláudia Borbinha, Filipa Serrazina, Manuel Salavisa, et al.
BMC Neurology, 2019
- Bismuth
- Brain Diseases
- Organometallic Compounds
Najdanović SM, Kostić MM, Petrović MM, et al.
2025
Bismuth basic nitrates (BBNs) were synthesized via an electrochemical method, i.e., by electrodeposition from an acidic solution of bismuth nitrate, followed by thermal treatment in an air environment. For the first time, the influence of various electrochemical parameters on the morphology, crystal structure, and chemical structure of BBNs was examined. The following synthesis parameters were investigated: electrodeposition current density, thermal treatment temperature of the obtained deposit, and working electrode material (cathode). The obtained materials were characterized by SEM-EDX, XRD, FTIR, TG, and N2 adsorption/desorption methods and were applied for the sorption of the textile dye RB19. The results showed that the electrodeposition current density and thermal treatment temperature affect the surface morphology, chemical composition, and crystal structure of the obtained materials, as well as the RB19 sorption efficiency. On the other hand, the working electrode material does not affect the properties of the synthesized materials mentioned. Kinetic, isotherm, and thermodynamic analysis of the sorption process were also examined.
Abstract licence: CC BY
Rahimah Idris, Ramiza Ramza Ramli, Wan NorSyafiqah W Yaacob, et al.
International Archives of Otorhinolaryngology, 2024
Abstract Introduction Tonsillectomy is one of the most common operations performed by otorhinolaryngology surgeons worldwide; however, the insufficient quality of the postoperative pain management and effective posttonsillectomy pain relief remain a clinical dilemma. Objective To evaluate the efficacy of applying bismuth iodine paraffin paste (BIPP) to the dissected fossa as an adjuvant therapy for a better outcome in terms of posttonsillectomy pain management and due to its wound healing properties. Methods The present is a prospective randomized control pilot study with 44 patients aged > 7 years who underwent tonsillectomy. The patients were divided into two groups: the control group and the group that had BIPP applied to the dissected tonsillar fossa. The visual analogue scale score and the post-onsillectomy percentage of tonsillar fossa epithelization were recorded and evaluated. Results Both subjectively and objectively, there a was statistically significant pain-relieving effect in the BIPP group within the first 5 postoperative days (p < 0.05). From postoperative day 3 onward, the dissected area of the tonsillar fossa healed significantly faster in the BIPP group compared with the control group, and it became stable on day 14. Conclusion The topical application of BIPP showed a better pain-relieving effect, it was safe, and hastened wound healing after tonsillectomy.
Abstract licence: CC BY 4.0
G J Crossland, A P Bath
The Journal of Laryngology & Otology, 2011
- Epistaxis
- Drug Hypersensitivity
- Nitrites
E. S. Koledova, Yu. M. Yukhin
Theoretical Foundations of Chemical Engineering, 2024
Nur Syazwani Mohd Salehuddin, Mohd Sazafi Mohd Saad, M. Doi, et al.
Egyptian Journal of Ear, Nose, Throat and Allied Sciences, 2024
D. Boglaienko, M. Bowden, N. Escobedo, et al.
Environmental Science: Water Research & Technology, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1 to 4 hours
Mechanism
Based on the findings of a clinical investigation in patients with duodenal ulce…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.2%
[A33012]…
Half-life
1 to 4 hours
[L2733]
Protein binding
[A33021]
Volume of distribution
[A33012]
Metabolism
Elimination
[A33021]
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 357 interactions
[L2733]
Nephropathy, encephalopathy, osteoarthropathy, gingivitis, stomatitis and colitis have been attributed to bismuth toxicity in humans .
[A33021]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A33012]
Approximately 0.2% of orally administered bismuth is absorbed systematically from the gastrointestinal tract with the peak plasma concentration typically occurring within 1 hour .
[L2733]
[L2733]
[A33021]
[A33012]
[A33021]
ATC A02BX12
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q126605705), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.